Please upgrade your browser.
Reduction of transforming growth factor- type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.
Composite renal cell carcinoma with clear cell renal cell carcinomatous and carcinoid tumoral elements: A first case report - Abstract.
To assess the accuracy of renal biopsy for predicting the final nuclear grade and histologic subtype. Small renal masses can be safely observed in select patients who are poor surgical candidates. Renal biopsy may help identify patients who are candidates for observation.
Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.
With the advent of the new targeted therapies there has been a complete shift in paradigm. Treatment options for patients with advanced disease have improved dramatically; until recently there was limited choice and therapies were poorly tolerated, with relatively low response rates. Patients now face multiple options with improved safety and efficacy, and there are plenty of further therapies in the pipeline. The overall prognosis has changed for these patients and survival is now much longer.
Contrary to claims made by some Democratic detractors, detailed GOP proposals, and a bipartisan bill with several GOP cosponsors, do exist.
Wideout crowned team champion in Xbox tourney as Nittany Lions look to call attention to Global Rare Disease Day. The action included a stunning upset in the first round.
A phase II clinical trial of ixabepilone , an epothilone B analog, in patients with metastatic renal cell carcinoma
This phase II study was conducted to assess the efficacy and safety of ixabepilone in patients with metastatic renal cell carcinoma. Ixabepilone can cause tumor regression in some patients with metastatic renal cell carcinoma and could be considered in combination regimens with other therapies.
|Powered by NeonCRM|